JP2016515621A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515621A5
JP2016515621A5 JP2016506360A JP2016506360A JP2016515621A5 JP 2016515621 A5 JP2016515621 A5 JP 2016515621A5 JP 2016506360 A JP2016506360 A JP 2016506360A JP 2016506360 A JP2016506360 A JP 2016506360A JP 2016515621 A5 JP2016515621 A5 JP 2016515621A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
lymphoma
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016506360A
Other languages
English (en)
Japanese (ja)
Other versions
JP6469077B2 (ja
JP2016515621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/032483 external-priority patent/WO2014165482A1/en
Publication of JP2016515621A publication Critical patent/JP2016515621A/ja
Publication of JP2016515621A5 publication Critical patent/JP2016515621A5/ja
Application granted granted Critical
Publication of JP6469077B2 publication Critical patent/JP6469077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016506360A 2013-04-02 2014-04-01 4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物 Active JP6469077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361807605P 2013-04-02 2013-04-02
US61/807,605 2013-04-02
PCT/US2014/032483 WO2014165482A1 (en) 2013-04-02 2014-04-01 Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers

Publications (3)

Publication Number Publication Date
JP2016515621A JP2016515621A (ja) 2016-05-30
JP2016515621A5 true JP2016515621A5 (cg-RX-API-DMAC7.html) 2017-05-18
JP6469077B2 JP6469077B2 (ja) 2019-02-13

Family

ID=50588939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506360A Active JP6469077B2 (ja) 2013-04-02 2014-04-01 4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物

Country Status (14)

Country Link
US (1) US9839632B2 (cg-RX-API-DMAC7.html)
EP (1) EP2981262A1 (cg-RX-API-DMAC7.html)
JP (1) JP6469077B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150136078A (cg-RX-API-DMAC7.html)
CN (1) CN105246480A (cg-RX-API-DMAC7.html)
AU (1) AU2014248263A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025252A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907908A1 (cg-RX-API-DMAC7.html)
EA (1) EA201591902A1 (cg-RX-API-DMAC7.html)
HK (1) HK1219896A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015013912A (cg-RX-API-DMAC7.html)
PH (1) PH12015502266A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507759WA (cg-RX-API-DMAC7.html)
WO (1) WO2014165482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018095377A1 (zh) 2016-11-24 2018-05-31 天津和美生物技术有限公司 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗
CN107875128A (zh) * 2017-12-06 2018-04-06 佛山市弘泰药物研发有限公司 一种泊马度胺口崩片及其制备方法
US20210069356A1 (en) * 2018-01-02 2021-03-11 Celgene Corporation Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
AU2020369497C1 (en) 2019-10-21 2026-05-07 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
IL292375A (en) 2019-10-21 2022-06-01 Celgene Corp Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use
CN114885602A (zh) * 2019-10-21 2022-08-09 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
WO2001080884A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
CA2430669C (en) * 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
US20120322779A9 (en) 2001-04-25 2012-12-20 Rhonda Voskuhl Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
AU2005311888A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
PL1907373T3 (pl) 2005-06-30 2013-05-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
PL1928492T3 (pl) 2005-09-01 2011-09-30 Celgene Corp Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080051431A1 (en) 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
US20110184025A1 (en) 2006-10-19 2011-07-28 Hensel Jennifer L Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases
CN101909609A (zh) 2007-11-08 2010-12-08 细胞基因公司 免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途
US20090148853A1 (en) 2007-12-07 2009-06-11 Schafer Peter H Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
US20100098657A1 (en) 2007-12-27 2010-04-22 Schafer Peter H Method of Treating Cancer with Immunomodulatory Compounds and IgG
WO2009105256A2 (en) 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
EP3351240B1 (en) * 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US20150297579A1 (en) 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject

Similar Documents

Publication Publication Date Title
NZ777261A (en) Combination of dextromethorphan and bupropion for treating depression
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
JP2009545600A5 (cg-RX-API-DMAC7.html)
KR20180100539A (ko) 치료용 조성물, 병용 및 적용과 관련된 사용방법
JP2017149726A5 (cg-RX-API-DMAC7.html)
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
JP2018507243A5 (cg-RX-API-DMAC7.html)
JP2016529285A5 (cg-RX-API-DMAC7.html)
MX2023001468A (es) Tratamiento de cancer de prostata.
JP2020516646A5 (cg-RX-API-DMAC7.html)
TW201244714A (en) PARP inhibitors for the treatment of CIPN
ZA202103820B (en) Capsule formulations
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
JP2018530578A5 (cg-RX-API-DMAC7.html)
JP2020530467A5 (cg-RX-API-DMAC7.html)
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2016515586A5 (cg-RX-API-DMAC7.html)
JP2018503610A5 (cg-RX-API-DMAC7.html)
JP2017537927A5 (cg-RX-API-DMAC7.html)
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2016509030A5 (cg-RX-API-DMAC7.html)
JP2021530543A5 (cg-RX-API-DMAC7.html)
US20210251963A1 (en) Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
JP2020536068A5 (cg-RX-API-DMAC7.html)
JP2020510011A5 (cg-RX-API-DMAC7.html)